Kempharm Stock Return On Equity
| KMPHDelisted Stock | USD 5.81 0.02 0.34% |
KemPharm fundamentals help investors to digest information that contributes to KemPharm's financial success or failures. It also enables traders to predict the movement of KemPharm Stock. The fundamental analysis module provides a way to measure KemPharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to KemPharm stock.
KemPharm |
KemPharm Company Return On Equity Analysis
KemPharm's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current KemPharm Return On Equity | -0.31 |
Most of KemPharm's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, KemPharm is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, KemPharm has a Return On Equity of -0.3124. This is 98.7% lower than that of the Pharmaceuticals sector and 99.14% lower than that of the Health Care industry. This indicator is about the same for all United States stocks average (which is currently at -0.31).
KemPharm Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses KemPharm's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of KemPharm could also be used in its relative valuation, which is a method of valuing KemPharm by comparing valuation metrics of similar companies.KemPharm is currently under evaluation in return on equity category among related companies.
KemPharm Fundamentals
| Return On Equity | -0.31 | |||
| Return On Asset | -0.0897 | |||
| Operating Margin | (1.72) % | |||
| Current Valuation | 97.06 M | |||
| Shares Outstanding | 34.5 M | |||
| Shares Owned By Insiders | 10.29 % | |||
| Shares Owned By Institutions | 17.68 % | |||
| Number Of Shares Shorted | 1.37 M | |||
| Price To Earning | 17.87 X | |||
| Price To Book | 1.69 X | |||
| Price To Sales | 14.16 X | |||
| Revenue | 28.65 M | |||
| Gross Profit | 26.59 M | |||
| EBITDA | (8.29 M) | |||
| Net Income | (8.55 M) | |||
| Cash And Equivalents | 80.98 M | |||
| Cash Per Share | 2.35 X | |||
| Total Debt | 16.16 M | |||
| Debt To Equity | 0.16 % | |||
| Current Ratio | 12.21 X | |||
| Book Value Per Share | 2.72 X | |||
| Cash Flow From Operations | 10.44 M | |||
| Short Ratio | 5.87 X | |||
| Earnings Per Share | (0.91) X | |||
| Target Price | 22.33 | |||
| Number Of Employees | 24 | |||
| Beta | 2.16 | |||
| Market Capitalization | 200.65 M | |||
| Total Asset | 132.94 M | |||
| Retained Earnings | (252.18 M) | |||
| Working Capital | 45.74 M | |||
| Current Asset | 54.08 M | |||
| Current Liabilities | 8.34 M | |||
| Z Score | 5.8 | |||
| Net Asset | 132.94 M |
About KemPharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze KemPharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of KemPharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of KemPharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards KemPharm in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, KemPharm's short interest history, or implied volatility extrapolated from KemPharm options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in KemPharm Stock
If you are still planning to invest in KemPharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the KemPharm's history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |